Jiankui they/them (@IC50_cent) profile picture
Joined October 2022
Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)Photo by Jiankui they/them (@IC50_cent)
Jiankui they/them retweeted
If I’m Boston College I’m walking off the field. If this is a fumble, their touchdown that was called off earlier in the game is a touchdown. It is the same exactly play. These refs are fishy to say the least.
4
5
23
2,292
I do appreciate the folks who put themselves out there.
11
1,790
Curve below is OS on PD1 retreat after progression by stage. 31% patients in IGNYTE were stage III which isn't even on here. Note Opdualag is comparator which has 20% risk reduction vs PD1 in 1L. When you adjust for these factors, it is unclear if RP1 is adding much/wins in RCT.
$repl- oh the irony... Nice timing (for those who claimed RP1 responses were a fluke) #asco26
3
612
$REPL crazy how the FDA published the CRL from a team under Pazdur citing trial design as a no-go and ppl on here acting like FDA accepting resub is 'right thing to do'. Let be honest there is no objective rationality for AA here, this is politics.
3
18
2,473
i hesitate to "dump" on @adamfeuerstein. i'm sure he means well! but this post confirms his core skill is mistaking condescension for expertise. he knows very little about prediction markets, incentive design, or what biotech desperately needs. old man, please reconsider.
1
7
844
$RVMD Did they comment on therapeutic index? Not sure how a more potent drug plays here when on target tox limited dose of the first gen…
New compound from @RevMedicines RM-055 disclosed at #AACR26 They took a subtle finding 👉🏽Daraxonrasib-CYPA complex modestly increasing RAS GTP hydrolysis 👉🏽 to build a RAS GAP on steroids. RM-055 flattens Daraxonrasib resistant tumors including RAS amplified cases across models.
1
6
3,304
btw $LRMR almost has no shot at AA. Skin fxn is not surrogate for CNS fxn, mFARS improvements in nonamb patients likely just placebo/noise, wont have 30 patients at 6m at filing because 36% discon rate in OLE, modified dosing regimen will only have data in handful of patients..
6
20
5,562
Straight up lying that fda rugpulled them when they said trial would be unapprovable in 2021. Making 4m a year. What an asshole. At what point do these guys start getting prosecuted for securities fraud?
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of @Replimune walks us through the program's timeline and history, and what this might mean for its future. $REPL Full video: biotechtv.com/post/sushil-pa…
1
13
1,824
$REPL CRL is WILD...these guys lied for fucking years. Also FDA is absolutely correct here, management story never made sense, cant comp Gr3 to Gr4 population. Also censoring PD in retreated patients is dirty. V little chance this beats opdualag on OS imo this company should die.
3
3
3
70
13,856
Looks like @DrPatrick blocked me like he did Cynviloq. Too bad anktiva can’t enhance the body’s ability to not be a massive pussy.
1
8
505
Fade chalamet tonight. No position.
1
709
Turns out the dog guys vaccine was given concomitant with pd1 and looking for investors…so basically the classic single arm io combo grift has now come to n=1 dog studies. Probably wasn’t even his dog tbh
6
13
2
164
7,960
Very techbro of the dog guy to sequence and use alphafold to find a bespoke therapy for a cancer that is almost unilaterally driven by KIT which has multiple approved inhibitors
7
18
1
295
28,333
IMO $CRVS drug looks inert on cytokine/T cell compartment (data slice & dice). Even if you don’t agree why did the first 2 cohorts with no action on biomarkers show efficacy on EASI? Company unblinded, CEO says last cut TARC doesn’t matter/il4 can’t be measured but have it now…
1
18
3,964
This is a masterclass in misinterpreting data
$NRIX +23% surprises me. I thought the #ASH25 data showed $ONC to be better on efficacy (with caveats), albeit worse on safety. My earlier take on @ApexOnco -> oncologypipeline.com/apexonc…
2
1,206
$NUVB What is PoS in HGG? In Natsume 2022 DS-1001 put up a 10.4wk PFS in enhancing tumors with 7wks time on drug (8/35 pts were low grade). $TNGX TNG908 put up < 8wks time on drug in gbm and terminated. Most of these HGGs no longer addicted to IDH1. Does this beat placebo on PFS?
1
2
946
Like your effectively betting on this blue curve indicating that drug is active in enough patients to beat a non-active control. I just don't know man. CR doesn't matter as primary is PFS. Also if drug wins with a 6m PFS what is the peak revs here? Vor not the right analog...
1
2
458
1. You've generated 0 evidence to prove claims. The post-hoc from IASCLC is retarted. 2. PD1+chemo sig better on OS/PFS HR vs PD1 alone, disproving this theory. 3. Your company is going to 0 unless you can put the screws on daddy trump. V transparent. Shit makes my blood boil
unavailable
3
1
16
8,202
Great news for $IBRX! Anktiva is the perfect bespoke therapy for the rare population of patients that don’t want to live!
unavailable
1
6
1,496